Swiss insulin devices provider CeQur has purchased certain assets from Johnson & Johnson Diabetes Care Companies subsidiary Calibra Medical for an undisclosed amount.

As part of the acquisition, CeQur gains exclusive worldwide licence to Calibra’s wearable, on-demand insulin delivery system that was formerly called OneTouch Via.

The system has been designed for the simple and convenient delivery of rapid-acting insulin at mealtime.

“As part of the acquisition, CeQur gains exclusive worldwide licence to Calibra’s wearable, on-demand insulin delivery system that was formerly called OneTouch Via.”

After the transfer of the associated manufacturing equipment, CeQur is planning to relaunch the Calibra system in mid next year under a new name.

The system is expected to complement CeQur’s basal and bolus insulin-infusion device, PAQ, which is also a wearable product developed to allow simple, discreet insulin delivery.

CeQur believes that the wearable devices will eliminate the need for multiple injections each day.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CeQur CEO Robert Farra said: “Clinical studies and real-world experience have shown that wearable, on-demand insulin delivery provides an ideal solution to the pervasive challenge of mealtime insulin delivery.

“The Calibra device is a perfect complement to PAQ, our basal and bolus insulin-infusion device. Both wearable devices provide simple, discreet, three-day insulin delivery without the barriers and discomfort created by injections.”

A recent clinical study reported to have demonstrated favourable clinical outcomes when the Calibra device’s capability to initiate and maintain bolus insulin dosing was compared to that of insulin pens.

Conducted in 278 type 2 diabetes patients at 62 sites, the trial showed that the Calibra system delivered positive clinical benefits, comparatively less glycaemic variability, significantly improved ease-of-use and patient satisfaction scores.

The safety profile of the device was found to be similar to the insulin pens.